Cranial RT timing was not associated with outcomes in HER2-positive breast brain metastases

Concurrent, deferred, or earlier cranial RT produced no significant survival difference in patients receiving pyrotinib for HER2-positive breast brain metastases.

KEY POINTS

  • This retrospective two-center cohort included 101 patients with HER2-positive breast cancer brain metastases treated with both cranial radiotherapy and pyrotinib between 2018 and 2025. Two-thirds had extracranial metastatic disease, 35.6% had received at least three prior systemic lines, and 35.6% had more than four brain metastases.
  • Patients were divided into three treatment sequences: concurrent pyrotinib plus RT (n=41), RT after intracranial progression on pyrotinib (n=38), and pyrotinib after intracranial progression following RT (n=22). Fifty-eight patients received focal RT and 43 received WBRT with or without a boost.
  • For the entire cohort, median CNS progression-free survival was 14.8 months and median overall survival 36.0 months. Estimated CNS-PFS was 57.9% at one year and 33.7% at two years, while two-year OS was 64.8%.
  • Treatment sequence did not significantly affect CNS-PFS: median values were 14.3, 15.0, and 21.4 months for concurrent therapy, RT after pyrotinib progression, and pyrotinib after RT progression, respectively (p=0.252).
  • Overall survival was likewise not significantly different: median OS was 33.0, 35.4, and 42.0 months, respectively (p=0.281). The apparently longer survival in the RT-first group is particularly vulnerable to guarantee-time bias because patients had to survive until progression before starting pyrotinib.
  • Focal radiotherapy was associated with longer OS than WBRT in multivariable analysis (HR 0.56, 95% CI 0.34–0.94; p=0.028), but this association weakened after propensity matching (HR 0.54, p=0.052). Focal treatment was preferentially used in patients with lower intracranial disease burden, so superiority cannot be established.
  • A data-derived threshold suggesting RT approximately 3.9 months before pyrotinib was associated with 49.9 versus 29.8 months median OS failed internal validation: permutation p=0.211 and optimism correction attenuated the HR from 0.31 to 0.66. Radiation necrosis occurred in 7/101 patients (6.9%), with no treatment-related deaths and no significant safety differences among sequencing groups.

CLINICAL TAKEAWAY

These data do not support a specific cranial RT–pyrotinib sequence for HER2-positive breast cancer brain metastases. The focal-RT survival signal is clinically interesting but remains vulnerable to indication bias, while the proposed 3.9-month timing threshold is explicitly hypothesis-generating and should not guide treatment decisions.

SOURCE

Clinical and Translational Radiation Oncology

Browse more research Suggest a correction